Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.


Osteoarthritis Pain Pipeline Drugs Market Report Overview

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides an overview of the Osteoarthritis Pain (Central Nervous System) pipeline landscape.

Osteoarthritis pain pipeline drugs market is the most common symptom associated with osteoarthritis which causes disruption of the cartilage. If the condition worsens, it leads to rubbing of the bones against each other causing even more pain and loss of movement. Risk factors are age, joint injury, obesity and heredity. Treatment includes weight control, exercise and medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis Pain – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 32, 10, 1, 16, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Osteoarthritis Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Osteoarthritis Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Osteoarthritis Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Osteoarthritis Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis Pain (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Osteoarthritis Pain (Central Nervous System).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Osteoarthritis Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Adolore Biotherapeutics Inc
AlzeCure Pharma AB
Ampio Pharmaceuticals Inc
Andros Pharmaceuticals Co Ltd
AntalGenics SL
Antibe Therapeutics Inc
Apimeds Inc
APT Therapeutics Inc
Aquilus Pharmaceuticals Inc
AstraZeneca Plc
Avecho Biotechnology Ltd
Axsome Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
BioTissue Inc
BriOri BioTech Inc
Centrexion Therapeutics Corp
Chromocell Corp
Concentric Analgesics Inc
Daewoong Pharmaceutical Co Ltd
Eccogene (Shanghai) Co Ltd
Eli Lilly and Co
Elite Pharmaceuticals Inc
Ensign Pharmaceutical Inc
Eupraxia Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Futura Medical Plc
Grunenthal GmbH
GSK plc
Levicept Ltd
Neumentum Inc
Novartis AG
Olatec Therapeutics LLC
OliPass Corporation
Overseas Pharmaceuticals Ltd
Pacira BioSciences Inc
Paradigm Biopharmaceuticals Ltd
Peptide Logic LLC
Pfizer Inc
Pharmnovo AB
Pike Therapeutics Inc
Propella Therapeutics Inc
ProteoThera Inc
Pure Green Pharmaceuticals Inc
Q-State Biosciences Inc
RaQualia Pharma Inc
Regeneron Pharmaceuticals Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sansho Co Ltd
Saol Therapeutics Inc
Shanghai Leado Pharmaceutical Technology Co Ltd
Shionogi & Co Ltd
Shulov Innovative Science Ltd
Sorrento Therapeutics Inc
Symic Bio Inc
Techfields Pharma Co Ltd
Tris Pharma Inc
Vertex Pharmaceuticals Inc
Virpax Pharmaceuticals Inc
Xalud Therapeutics Inc
Xgene Pharmaceutical Inc
Xintela AB
Yooyoung Pharm Co Ltd
Zhejiang Yatai Pharmaceutical Co Ltd
ZYUS Life Sciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Osteoarthritis Pain – Overview

Osteoarthritis Pain – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteoarthritis Pain – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteoarthritis Pain – Companies Involved in Therapeutics Development

Osteoarthritis Pain – Drug Profiles

Osteoarthritis Pain – Dormant Projects

Osteoarthritis Pain – Discontinued Products

Osteoarthritis Pain – Product Development Milestones

Featured News & Press Releases

Jul 18, 2022: OliPass moves forward to second stage of phase 2a trial for pain killer OLP-1002

Jul 01, 2022: PARA_OA_008 study evaluating Zilosul mechanism and disease modifying effects completes recruitment

Jun 27, 2022: Virpax will pursue direct to OTC Pathway for Epoladerm for pain associated with osteoarthritis

Jun 01, 2022: AlzeCure’s abstract on pain Project TrkA-NAM accepted for presentation at IASP 2022

May 02, 2022: Gordon Robert Alton, PhD joins BriOri BioTech as COO to develop patented topical formulation of Vioxx providing those suffering with osteoarthritis a long lasting non-opioid option for pain relief

Apr 20, 2022: Ampio provides regulatory update

Mar 22, 2022: Virpax completes all FDA-required pre-clinical studies for Epoladerm

Mar 09, 2022: BriOri BioTech granted patent for topical formulation of Vioxx

Mar 02, 2022: Xalud Therapeutics doses first patient in phase 2a trial of XT-150 for the treatment of facet joint osteoarthritis pain

Feb 15, 2022: BriOri BioTech granted patent for topical formulation of Rofecoxib

Dec 17, 2021: Xalud Therapeutics receives FDA Fast Track Designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee

Dec 07, 2021: Sorrento begins enrollment in phase 2 trial of resiniferatoxin (RTX) for the treatment of pain due to knee osteoarthritis (OA)

Nov 03, 2021: Paradigm’s Investigational New Drug (IND) application cleared by the US FDA.

Oct 26, 2021: Paradigm: Phase 2 synovial fluid biomarker study update

Oct 14, 2021: Antibe Therapeutics provides update on Otenaproxesul and expanded drug pipeline




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


Frequently asked questions

Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Osteoarthritis Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.